Local Vape Retailer Faces Legal Action for Non-compliant Products and Counterfeit Cigarettes

Aug.02.2023
Local vape retailer, J&M Patterson Ltd, faces legal action for selling non-compliant nicotine vape products and counterfeit cigarettes.

Title: Local Vape Retailer Faces Legal Action for Non-compliant Products and Counterfeit Cigarettes

 

In a recent development, Muhammed Shuaab, director of J&M Patterson Ltd, a local nicotine vape retailer located at 33-35 High Street, Alness, has been subjected to legal requirements and restrictions by Tain Sheriff Court. The court order was issued by the High Council Trading Standards following intelligence that Shuaab was selling nicotine vapor (NVP or vape) products that did not comply with product safety and labeling requirements.

 

After a visit and warning from Trading Standards Officers, it was discovered that Shuaab had over 1000 NVPs in his possession that violated the product safety regulations. Consequently, these non-compliant products will now be confiscated and destroyed.

 

The Tobacco and Related Products Regulations 2016 state that the sale or possession of NVPs that do not comply with these rules is considered an offense. Offenders can be sentenced up to 12 months in prison or face a fine of up to £5,000, or both.

 

Particular concern arises from the potential health risks associated with unsafe NVPs lacking proper instructions, warnings, and information, especially for vulnerable individuals. The High Council's Trading Standards also suspects that retailers may be distributing single-use vapes with high nicotine concentrations.

 

Aside from product compliance, the court order imposes specific requirements on the retailer. Mr. Shuaab, as a registered business, is obligated to enforce a strict age verification policy to prevent the sale of NVPs to individuals under 18. Failure to comply with this policy is considered a criminal offense. Furthermore, Mr. Shuaab has been legally mandated to seek written authorization from persons under 18 before selling nicotine vapor products to them.

 

In addition to the non-compliant NVPs, a sleeve of "Richmond Blue" cigarettes, amounting to 200 cigarettes, was found in Shuaab's possession. These cigarettes, suspected to be counterfeit, were seized and handed over to the trademark holder for examination. Counterfeit cigarettes often contain harmful ingredients and lack legal liability for their safety.

 

The unauthorized sale of non-compliant NVPs and possession of counterfeit cigarettes are offenses under the Consumer Protection from Unfair Trading Regulations 2008. Shuaab's actions indicate a breach of the law, as he either falsely declared or intentionally created a misleading impression about his products.

 

Lastly, Shuaab is required to inform the Highland Council of any changes to his business name, personal name, or address for the next five years.

 

This order serves as a warning to all retailers to ensure compliance with product safety regulations and to refrain from engaging in the sale of counterfeit goods. The High Council Trading Standards will continue to monitor and take legal action against those who endanger public health and violate consumer protection laws.

 

Summary: Tain Sheriff Court has issued a court order against Muhammed Shuaab, a local nicotine vape retailer, for selling non-compliant NVPs and possessing counterfeit cigarettes. The order mandates compliance with product safety regulations, age verification policies, and the notification of changes to business details. Failure to adhere to these requirements can lead to imprisonment or fines. The High Council Trading Standards highlights the health risks associated with unsafe NVPs and the potential harm caused by counterfeit cigarettes.


Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Eleftheria (Ria) Kioupritzi, a biopharmaceutical professional with more than 15 years of experience, has joined Philip Morris International as Director Scientific Affairs within Corporate Affairs. She previously served at Roche as Senior Scientific Communications Director for Neuroscience and Rare Diseases and worked extensively in spinal muscular atrophy. Her earlier career also covered competitive intelligence, clinical and regulatory monitoring, pipeline development and launch preparation. During her time working in Roche's SMA field, Evrysdi passed through several U.S. FDA milestones, including its initial approval, an expanded indication for younger infants and approval of a tablet formulation. Public records do not show that Kioupritzi herself led the FDA submissions.
Sep.22
Product | PMI Japan Expands ZYN by IQOS Strength Portfolio With Strong Series, Increasing Lineup to 12 Products
Product | PMI Japan Expands ZYN by IQOS Strength Portfolio With Strong Series, Increasing Lineup to 12 Products
Philip Morris Japan (PMJ) has expanded the ZYN by IQOS oral tobacco pouch portfolio in Japan with four new ZYN Strong products, adding a third intensity level alongside the existing Low and Medium ranges. The Strong series first entered selected duty-free channels in Japan on July 1, 2026, before expanding to IQOS stores, the ZYN Online Store and selected tobacco retailers from August 18. The expansion increases the Japanese ZYN by IQOS lineup from eight to 12 products.
Aug.20
Inside Nicotine-Pouch M&A Through Imperial's Yoik Deal: Latham, KPMG, PwC, Goldman Sachs and Morgan Stanley Form the Adviser Lineup
Inside Nicotine-Pouch M&A Through Imperial's Yoik Deal: Latham, KPMG, PwC, Goldman Sachs and Morgan Stanley Form the Adviser Lineup
Imperial Brands' acquisition of Swedish Helwit owner Yoik Group AB has highlighted the professional-services firms supporting cross-border oral nicotine M&A. Latham & Watkins and KPMG advised Imperial, while PwC and TM & Partners advised Yoik. KPMG also appeared on Imperial's acquisition of Black Buffalo earlier in 2026, while PwC played an extensive role in KT&G's acquisition of Swedish nicotine-pouch company Another Snus Factory. Imperial's public disclosures put the global modern oral nicotine delivery market at approximately £8.8 billion in retail sales and 23.5 billion pouches in 2024
Sep.20
Altria’s USSTC Starts $250 Million Kentucky Expansion, Adding More Than 200 Jobs
Altria’s USSTC Starts $250 Million Kentucky Expansion, Adding More Than 200 Jobs
U.S. Smokeless Tobacco Company, an Altria Group company, has broken ground on an approximately $250 million manufacturing expansion in Hopkinsville, Kentucky. The roughly 270,000-square-foot facility is expected to create more than 200 jobs and absorb processing, manufacturing and packaging operations currently split between Hopkinsville and Nashville, Tennessee. USSTC previously said production at its Nashville facility is expected to wind down by early 2028. The project forms part of Altria’s broader effort to modernize and consolidate its U.S. smokeless tobacco manufacturing network.
Sep.10
As JUUL2 Wins FDA Authorization, Harm Reduction Journal Highlights the Role of Real-World Evidence in Nicotine Product Regulation
As JUUL2 Wins FDA Authorization, Harm Reduction Journal Highlights the Role of Real-World Evidence in Nicotine Product Regulation
A commentary published in the international open-access, peer-reviewed Harm Reduction Journal argues that randomized controlled trials remain central to evaluating smoking cessation efficacy but cannot alone capture real-world uptake, complete switching, longer-term use and population impact of non-combustible nicotine products such as e-cigarettes, heated tobacco and nicotine pouches. The authors frame impact as “reach × efficacy” and call for real-world evidence to complement RCTs. Three days after publication, the FDA authorized three JUUL2 products and highlighted complete switching among adult smokers in explaining its decision, providing a timely regulatory backdrop to the debate.
Sep.08
Ohio Supreme Court Weighs Whether State Consumer Law Can Restrict Flavored Vape Sales
Ohio Supreme Court Weighs Whether State Consumer Law Can Restrict Flavored Vape Sales
The Ohio Supreme Court is hearing a case involving flavored vape sales and whether state authorities can use consumer protection laws to take action against retailers selling unauthorized vape products. Ohio officials argue that selling unauthorized flavored vapes may constitute consumer deception, while retailers argue that tobacco product regulation falls under federal Food and Drug Administration (FDA) authority and that states cannot impose additional restrictions through consumer laws. The case could affect the scope of state-level vape regulation across the United States.
Aug.06